About Gan & Lee Pharmaceuticals Co., Ltd.
Gan & Lee Pharmaceuticals is a Beijing biopharmaceutical company founded in 1998 and listed in Shanghai (603087.SH), centred on independent innovation. Its official English website defines its mission as delivering high-quality medicines and services to improve lives worldwide, with deep expertise in endocrine and metabolic therapeutic areas.
The company was the first in China to industrialise recombinant insulin analogues and spearheaded the transformation of the country's insulin industry, offering a full portfolio of long-acting, rapid-acting and premixed insulin products. In the 2024 national volume-based procurement for insulin it secured the largest total contracted volume among winning bidders in its category, according to the company.
Gan & Lee is now expanding its research into oncology, autoimmune diseases and gene and cell therapies, with peptide, PROTAC, oligonucleotide and antibody platforms, integrated R&D and manufacturing facilities in Beijing and Linyi, Shandong, over eighty international registration certificates and products sold in more than twenty-one countries across Eurasia, Asia-Pacific, Latin America and Africa.
The company was the first in China to industrialise recombinant insulin analogues and spearheaded the transformation of the country's insulin industry, offering a full portfolio of long-acting, rapid-acting and premixed insulin products. In the 2024 national volume-based procurement for insulin it secured the largest total contracted volume among winning bidders in its category, according to the company.
Gan & Lee is now expanding its research into oncology, autoimmune diseases and gene and cell therapies, with peptide, PROTAC, oligonucleotide and antibody platforms, integrated R&D and manufacturing facilities in Beijing and Linyi, Shandong, over eighty international registration certificates and products sold in more than twenty-one countries across Eurasia, Asia-Pacific, Latin America and Africa.